Surgical site infection after pancreaticoduodenectomy is often caused by pathogens resistant to standard prophylactic antibiotics, suggesting that broad-spectrum antibiotics may be more effective prophylactic agents. This article describes the rationale and methodology underlying a multicenter randomized trial evaluating piperacillin-tazobactam compared with cefoxitin for surgical site infection prevention following pancreaticoduodenectomy. As the first US randomized surgical trial to utilize a clinical registry for data collection, this study serves as proof of concept for registry-based clinical trials.
Keywords: antibiotic prophylaxis; cefoxitin; clinical trial; pancreaticoduodenectomy; piperacillin; surgical wound infection; tazobactam drug combination.
© 2021 Wiley Periodicals LLC.